The UWM Research Foundation is proud to announce four Catalyst Grants for projects that include a new purification system for antibodies; online self-administered diagnostic program for psychiatric disorders; a power hand rehabilitation glove for home use; and an easier two-line breeding system for sorghum hybrids. These projects feature strong research teams and three new researchers that have not been previously funded.
Promentis Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing innovative therapies for neuropsychiatric disorders, today announced that it has commenced a Phase 1 single ascending dose study for its lead compound, SXC-2023. Promentis is developing SXC-2023 and other compounds that engage System xc-, a central nervous system (CNS) target addressing glutamatergic imbalance and oxidative stress, to treat obsessive-compulsive and related disorders, substance-related and addictive disorders and other neuropsychiatric disorders. SXC-2023 has demonstrated a compelling profile across a range of non-clinical studies.